澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ACDC Metals Ltd

0.056

0.000

成交量：- -

成交額：- -

市值：419.61萬

市盈率：-5.94

高：0.056

開：0.056

低：0.056

收：0.056

52周最高：0.160

52周最低：0.036

股本：7,493.08萬

流通股本：4,028.75萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.009

每股收益(LYR):-0.009

淨資產收益率：-6.71%

總資產收益率：-2.92%

市淨率：0.41

市盈率(LYR):-5.94

資料載入中...

總覽公司新聞資訊公告

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

先聲藥業(02096.HK)：SIM0609(CDH17抗體偶聯藥物)獲國家藥品監督管理局簽發藥物臨床試驗批准通知書

招銀國際：首次覆蓋維立志博-B(09887.HK)予「買入」評級目標價63.5港元

阿斯利康第二款ADC藥物在國內獲批用於乳腺癌

阿斯利康宣佈注射用德達博妥單抗（達卓優）正式在國內獲批用於治療既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不

研報掘金｜中金：上調藥明合聯目標價至75港元中期業績勝預期且訂單增長強勁

德琪醫藥-B(06996.HK)：ATG-022就治療胃癌/胃食管結合部腺癌獲授予突破性治療藥物認定

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ADC.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.056,"timestamp":1772060919283,"preClose":0.056,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"ACDC Metals Ltd","floatShares":40287509,"shares":74930755,"eps":-0.00943,"marketStatus":"交易中","change":0,"latestTime":"02-26 10:33:53 AEDT","open":0.056,"high":0.056,"low":0.056,"amount":0,"amplitude":0,"askPrice":0.06,"askSize":10000,"bidPrice":0.054,"bidSize":18425,"shortable":3,"etf":0,"ttmEps":-0.00943,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1772082000000},"marketStatusCode":2,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.056,"openAndCloseTimeList":[[1772060400000,1772082000000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":40287509,"roa":"-2.92%","roe":"-6.71%","lyrEps":-0.00943,"shares":74930755,"dividePrice":0,"high":0.056,"amplitude":0,"preClose":0.056,"low":0.056,"week52Low":0.036,"pbRate":"0.41","psRate":"12.18","week52High":0.16,"institutionHeld":0,"latestPrice":0.056,"committee":0.296394,"eps":-0.00943,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.00943,"open":0.056,"prevYearClose":0.065,"prevWeekClose":0.057,"prevMonthClose":0.049,"prevQuarterClose":0.065,"fiveDayClose":0.057,"twentyDayClose":0.055,"sixtyDayClose":0.068},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576048378","title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2576048378","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576048378?lang=zh_tw&edition=fundamental","pubTime":"2025-10-18 22:46","pubTimestamp":1760798760,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan (佳泰莱) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative  breast cancer  was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University . Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration  and was included in the priority review and approval process.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-positive-results-of-phase-3-clinical-study-optitrop-breast02-for-sacituzumab-tirumotecan-in-advanced-hrher2--breast-cancer-at-2025-esmo-302588212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4190","BK4080","BK7095","HR","ADC","BK4225","BK4203","BC","ADC.AU","BK4231"],"gpt_icon":0},{"id":"2565899846","title":"先聲藥業(02096.HK)：SIM0609(CDH17抗體偶聯藥物)獲國家藥品監督管理局簽發藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2565899846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565899846?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 20:12","pubTimestamp":1757333548,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4231","BK1191","BK4080","BK1583","02096","BK7095","ADC.AU","ADC"],"gpt_icon":0},{"id":"2564325557","title":"招銀國際：首次覆蓋維立志博-B(09887.HK)予「買入」評級 目標價63.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564325557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564325557?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 14:14","pubTimestamp":1756966477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","PD","BK4023","LU1169590202.USD","ADC","LU1169589451.USD","BK1161","ADC.AU","BK4231","BK4080","BK7095"],"gpt_icon":0},{"id":"2561474908","title":"阿斯利康第二款ADC藥物在國內獲批用於乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474908","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474908?lang=zh_tw&edition=fundamental","pubTime":"2025-08-22 20:38","pubTimestamp":1755866311,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AZN","LU0320765992.SGD","LU2462157665.USD","ADC.AU","BK4231","ADC","BK4568","HR","BK4007","BK4080","BK4203","LU2417539215.USD","LU0109394709.USD","BK7095","BK4225","LU2236285917.USD","BK4588","LU0889565916.HKD","LU2456880835.USD","LU1829250122.USD","BK4585"],"gpt_icon":0},{"id":"2561474158","title":"阿斯利康宣佈注射用德達博妥單抗（達卓優）正式在國內獲批用於治療既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474158?lang=zh_tw&edition=fundamental","pubTime":"2025-08-22 20:38","pubTimestamp":1755866311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4231","BK4585","LU1829250122.USD","ADC.AU","LU0320765992.SGD","BK4568","LU2462157665.USD","LU2417539215.USD","LU2236285917.USD","ADC","AZN","LU2456880835.USD","BK4203","BK4225","LU0109394709.USD","BK4588","BK4007","BK4080","LU0889565916.HKD","BK7095","HR"],"gpt_icon":0},{"id":"2560128083","title":"研報掘金｜中金：上調藥明合聯目標價至75港元 中期業績勝預期且訂單增長強勁","url":"https://stock-news.laohu8.com/highlight/detail?id=2560128083","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560128083?lang=zh_tw&edition=fundamental","pubTime":"2025-08-20 11:40","pubTimestamp":1755661213,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e0480a0531217974a0c2963e4454991e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["ADC","ADC.AU","SG9999014674.SGD","BK4080","02268","BK7095","BK1141","BK4231","159938","LU2488822045.USD","BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2560151287","title":"德琪醫藥-B(06996.HK)：ATG-022就治療胃癌/胃食管結合部腺癌獲授予突破性治療藥物認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2560151287","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560151287?lang=zh_tw&edition=fundamental","pubTime":"2025-08-19 12:23","pubTimestamp":1755577393,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK7050","BK1191","LU1223082196.USD","BK4080","BK4231","BK1574","BK4017","BK7095","CDE","ADC.AU","LU1223083913.SGD","LU1223082519.USD","ADC","06996","BK1583","CDE.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}